Dublin, Feb. 09, 2017 -- Research and Markets has announced the addition of the "Norovirus Forecast for selected Asian Markets 2017-2027" report to their offering.
Currently, there are six recognized norovirus genogroups, three of which (GI, GII, and GIV) affect humans. More than 25 different genotypes have been identified within these three genogroups. Variants of the GII.4 genotype are the most common cause of norovirus outbreaks.
This report provides the current incident population for Norovirus across Selected Asian Markets (Cambodia, Indonesia, Lao PDR and Vietnam) split by gender and 5-year age cohort. Along with the current incidence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team, several of the main symptoms of Norovirus have been quantified and presented alongside the overall incidence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Signs and symptoms of norovirus infection include:
- Nausea
- Vomiting
- Abdominal pain or cramps
- Watery or loose diarrhoea
- Malaise
- Low-grade fever
- Muscle pain
Reasons to Buy:
- Able to quantify patient populations in global Norovirus's market to target the development of future products, pricing strategies and launch plans.
- Gain further insight into the incidence of the subdivided types of Norovirus and identify patient segments with high potential.
- Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
- Identify sub-populations within Norovirus which require treatment.
- Gain an understanding of the specific markets that have the largest number of Norovirus patients.
Key Topics Covered:
1. Introduction
2. Cause of the Disease
3. Risk Factors & Prevention
4. Diagnosis of the Disease
5. Variation by Geography/Ethnicity
6. Disease Prognosis & Clinical Course
7. Methodology for quantification of patient numbers
8. Top-line Estimated Incidence for Norovirus
9. Norovirus in Vietnam
10. Abbreviations used in the report
11. Patient-Based Offering
12. Online Pricing Data and Platforms
13. References
14. Appendix
For more information about this report visit http://www.researchandmarkets.com/research/q7lfn6/norovirus
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Infectious Diseases Drugs, Gastrointestinal Drugs


OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 



